Potent Immunomodulators Developed from an Unstable Bacterial Metabolite of Vitamin B2 Biosynthesis

Angew Chem Int Ed Engl. 2024 Jul 29;63(31):e202400632. doi: 10.1002/anie.202400632. Epub 2024 Jun 26.

Abstract

Bacterial synthesis of vitamin B2 generates a by-product, 5-(2-oxopropylideneamino)-d-ribityl-aminouracil (5-OP-RU), with potent immunological properties in mammals, but it is rapidly degraded in water. This natural product covalently bonds to the key immunological protein MR1 in the endoplasmic reticulum of antigen presenting cells (APCs), enabling MR1 refolding and trafficking to the cell surface, where it interacts with T cell receptors (TCRs) on mucosal associated invariant T lymphocytes (MAIT cells), activating their immunological and antimicrobial properties. Here, we strategically modify this natural product to understand the molecular basis of its recognition by MR1. This culminated in the discovery of new water-stable compounds with extremely powerful and distinctive immunological functions. We report their capacity to bind MR1 inside APCs, triggering its expression on the cell surface (EC50 17 nM), and their potent activation (EC50 56 pM) or inhibition (IC50 80 nM) of interacting MAIT cells. We further derivatize compounds with diazirine-alkyne, biotin, or fluorophore (Cy5 or AF647) labels for detecting, monitoring, and studying cellular MR1. Computer modeling casts new light on the molecular mechanism of activation, revealing that potent activators are first captured in a tyrosine- and serine-lined cleft in MR1 via specific pi-interactions and H-bonds, before more tightly attaching via a covalent bond to Lys43 in MR1. This chemical study advances our molecular understanding of how bacterial metabolites are captured by MR1, influence cell surface expression of MR1, interact with T cells to induce immunity, and offers novel clues for developing new vaccine adjuvants, immunotherapeutics, and anticancer drugs.

Keywords: Biological activity; Chemical tools; Covalent ligands; Immunology; Natural Products; Protein folding; Schiff bases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigen-Presenting Cells / immunology
  • Antigen-Presenting Cells / metabolism
  • Histocompatibility Antigens Class I / immunology
  • Histocompatibility Antigens Class I / metabolism
  • Humans
  • Immunologic Factors / chemistry
  • Immunologic Factors / metabolism
  • Immunologic Factors / pharmacology
  • Immunomodulating Agents / chemistry
  • Immunomodulating Agents / metabolism
  • Immunomodulating Agents / pharmacology
  • Minor Histocompatibility Antigens / metabolism
  • Mucosal-Associated Invariant T Cells / immunology
  • Mucosal-Associated Invariant T Cells / metabolism
  • Ribitol / analogs & derivatives
  • Riboflavin* / analogs & derivatives
  • Riboflavin* / biosynthesis
  • Riboflavin* / chemistry
  • Riboflavin* / metabolism
  • Riboflavin* / pharmacology
  • Uracil / analogs & derivatives

Substances

  • Riboflavin
  • Immunomodulating Agents
  • Histocompatibility Antigens Class I
  • Minor Histocompatibility Antigens
  • MR1 protein, human
  • 5-(2-oxopropylideneamino)-6-d-ribitylaminouracil
  • Immunologic Factors
  • Ribitol
  • Uracil